The Great Debate: AI in Rheumatology
Drs. Mrinalini Dey, Jeffrey Curtis and Jinoos Yazdany
Watch video →What's hot
View all perspectives
What's Hot
RA: Inject the Steroids
Dr. Richard Conway reports on abstract 1355, "Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance of being off steroids and escalation of therapy at 1 year," presented at the 2025 ACR Convergence meeting in Chicago.
Watch video →
ACR2025 CAR-T Topic Panel
A focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping CAR-T practice right now. Panelists: Drs. Al Kim, Philip Mease, Yuz Yusof, Akhil Sood, and Jack Cush.
Watch video →
Tapering in SELECT GCA: Steroids are the Problem
Dr. Mike Putman reports on abstract 0895 (Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial) presented at the 2025 ACR Convergence meeting in Chicago.
Watch video →
Specialized Biomarkers in PsA
Dr. Elaine Husni reports on abstract 0111 (Predicting Response To Adalimumab In Patients With Psoriatic Arthritis Using Epigenetic Chromosome Conformation Signatures).
Watch video →
Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA
At ACR Convergence 2025, abstract 1039 entitled, “Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis” adds a critical dimension to the growing enthusiasm around cellular therapies in autoimmune disease.
Read more →
Day 4 Recap: ACR Convergence 2025 Highlights
Join panelists Drs. Brian Jaros, Akhil Sood and Michael Putman as they recap highlights from Day 4, the final day of the 2025 ACR Convergence meeting in Chicago.
Watch video →
Weight Loss as a Therapeutic Goal in Psoriatic Arthritis
Psoriatic arthritis (PsA) is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At ACR Convergence 2025, three compelling studies spanning pharmacologic, lifestyle, and longitudinal observational data converged on a central theme: weight loss is a powerful modulator of PsA outcomes, regardless of the intervention used.
Read more →
ACR 2025 - Day 3 Report
Day 3 in Chicago is hump day, the last big full day of presentations and posters. The day began with an 8AM plenary session, which brings me to the first of my three notables from today:
Read more →
The Great Debate – Who Really Won?
My favorite session at ACR Convergence is often the “Great Debate.” The debate this year also evaluated one of my favorite topics – ultrasound in giant cell arteritis (GCA). More specifically, it asked the question of whether biopsy or ultrasound should be the preferred modality for diagnosing GCA.
Read more →
What's the latest in PsA?
Dr. Peter Nash highlights key studies presented at the 2025 ACR Convergence meeting.
Watch video →
Is it All About the Weight Loss?
Dr. Jeffrey Curtis discusses two abstracts about the use of GLP-1 drugs and their impact beyond weight loss.
Watch video →
Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention
At ACR 2025, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological aging and to consider how nutrition and exercise can serve as integrative lifestyle interventions.
Read more →
Secrets and Pearls in Rheumatology
Dr. Janet Pope reports on secrets and pearls in rheumatology, from a session presented at the 2025 ACR Convergence meeting in Chicago
Watch video →
Perspectives on CAR T Therapy
Dr. Philip Mease offers his perspective on and takeaways from CAR-T therapy studies presented this week at the 2025 ACR Convergence meeting in Chicago.
Watch video →
The Long View of Diagnostic Delay in Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) remains a diagnostic challenge, particularly in its early stages before structural sacroiliitis is visible on imaging.
Read more →
When the Back Hurts: uncovering BASDAI drivers in PsA
Dr. Elaine Husni reports on abstract 1426 (Understanding the Drivers of BASDAI and Back Pain Scores in Psoriatic Arthritis).
Watch video →
Spondyloarthritis: The CLASSIC Study
Dr. Atul Deodhar reports on plenary session abstract 0854 (The ASAS and SPARTAN Revised Classification Criteria for Axial Spondyloarthritis: Development and Validation in the Classification of Axial SpA Inception Cohort Study).
Watch video →
Here are 3 abstracts that caught my eye on Day 2 at ACR25. Notably these have takeaway messages that should support your current practices.
CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure.
A growing arsenal of therapeutic targets in psoriatic arthritis (PsA) has enhanced the landscape of treatment in patients with this disease.
Two pivotal studies led by an international team of rheumatology experts will be presented at ACR Convergence 2025, showcasing major strides in the ultrasound-based diagnosis of enthesitis in psoriatic arthritis (PsA).
In recent years, data has emerged suggesting that female patients with spondyloarthritis, both psoriatic arthritis and axial spondyloarthritis, may have worse outcomes than male patients. A number of post-hoc analyses of randomised controlled trials of both TNF inhibitors and IL-17 inhibitors suggest that this phenomenon is also manifested in the responses to these agents; female patients do less well than male patients. The mechanisms behind
As the population ages globally, rheumatologists are caring for an increasingly older patient population more than ever before. In RA alone, nearly 40 percent of patients are now aged 65 years or older. Yet the evidence guiding our treatment decisions continues to come from studies that rarely include them, giving rise to a fundamental question: do we really know how best to treat older adults with rheumatic diseases?
New research presented at ACR Convergence 2025 highlights how the Rheumatology Informatics System for Effectiveness (RISE) registry—the nation’s largest collection of electronic health record data from rheumatology practices—is driving transformative improvements in quality, safety, and patient outcomes across rheumatic and musculoskeletal diseases.
The GLP-1 story has been hard to miss this year, and at ACR Convergence, it’s clear that these drugs are starting to make real waves in rheumatology. Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our patients.
ACR 2025 began today in Chicago with throngs of rheumatologists, fellows, ARP members, APPs and pharma folk taking to the meeting halls and rooms for tons of novel content.
A transformation is now underway in rheumatology, where cellular and immune therapies are redefining how we treat autoimmune diseases.
The RheumNow Faculty have run through day one at ACR25 and come with a few of their favorites - some what you expected but some of these are gems.
At ACR Convergence 2025, the American College of Rheumatology’s annual meeting, researchers presented pivotal Phase III studies highlighting novel therapeutic options for patients with gout, particularly those with limited treatment choices or uncontrolled disease. The findings underscore continuing progress in addressing a significant unmet need for safer, more effective therapies in this common and often debilitating condition.
At ACR Convergence 2025, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. Studies presented at the meeting highlighted issues ranging from kidney transplant outcomes in lupus to medication disparities in rheumatoid arthritis and demographic patterns in systemic sclerosis and axial spondyloarthritis.
Is there ‘bang for the buck’ using big data to help predict who will develop RA in at-risk populations and similarly to predict response to csDMARDs, TNFi and JAKi in RA?
The pharmacology treatment including biologics, cellular-based therapies, and Bi-specific T-cell Engager (BiTE) in systemic lupus erythematosus (SLE) is a rapidly expanding field of research that provides excitement and optimism to both the patients and the physicians.
Poster Hall